Eplontersen + Placebo
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Transthyretin Amyloid Cardiomyopathy
Conditions
Transthyretin Amyloid Cardiomyopathy
Trial Timeline
Dec 1, 2023 → Jan 5, 2027
NCT ID
NCT06194825About Eplontersen + Placebo
Eplontersen + Placebo is a phase 3 stage product being developed by AstraZeneca for Transthyretin Amyloid Cardiomyopathy. The current trial status is active. This product is registered under clinical trial identifier NCT06194825. Target conditions include Transthyretin Amyloid Cardiomyopathy.
What happened to similar drugs?
3 of 18 similar drugs in Transthyretin Amyloid Cardiomyopathy were approved
Approved (3) Terminated (0) Active (15)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06194825 | Phase 3 | Active |
| NCT04136171 | Phase 3 | Active |
Competing Products
20 competing products in Transthyretin Amyloid Cardiomyopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Eplontersen Solution for Injection | AstraZeneca | Phase 1 | 29 |
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 44 |
| Treatment of transthyretin (ATTR) amyloidosis in observational study setting | AstraZeneca | Pre-clinical | 33 |
| Eplontersen | AstraZeneca | Phase 3 | 47 |
| NNC6019-0001 + Placebo (NNC6019-0001) | Novo Nordisk | Phase 3 | 47 |
| NNC6019-0001 | Novo Nordisk | Phase 2 | 39 |
| NNC6019-0001 + Placebo (NNC6019-0001) | Novo Nordisk | Phase 2 | 35 |
| Coramitug | Novo Nordisk | Phase 1 | 36 |
| Tafamidis | Pfizer | Pre-clinical | 26 |
| Tafamidis | Pfizer | Pre-clinical | 30 |
| tafamidis meglumine | Pfizer | Approved | 43 |
| Fx-1006A | Pfizer | Phase 2 | 35 |
| Tafamidis | Pfizer | Phase 3 | 40 |
| Tafamidis 61 milligrams | Pfizer | Pre-clinical | 26 |
| Treatment for TTR amyloidosis + Treatment for TTR amyloidosis | Pfizer | Pre-clinical | 26 |
| Vyndaqel | Pfizer | Pre-clinical | 26 |
| tafamidis | Pfizer | Phase 3 | 40 |
| Tafamidis | Pfizer | Approved | 43 |
| Tafamidis | Pfizer | Pre-clinical | 26 |
| Vyndamax (tafamidis 61mg) | Pfizer | Pre-clinical | 30 |